SAN MATEO, Calif.--(BUSINESS WIRE)--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results